Tech Company Financing Transactions

Arch Oncology Funding Round

Lightchain, 3x5 Special Opportunity Partners and RiverVest Venture Partners participated in a $50 million Series B funding round for Arch Oncology. The round was announced on 3/26/2019.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

2000 Sierra Point Pkwy. 700
Brisbane, CA 94005
USA

Phone

Undisclosed

Website

www.archoncology.com

Email Address

[email protected]

Overview

Arch Oncology is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of best-in-class antibody therapies for the treatment of patients with cancer. Our next-generation anti-CD47 antibodies are highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Laurence Blumberg

        

Chief Medical Officer

Jackie Walling

        

Chief Operating Officer

Ronald Krasnow

        

Chief Scientific Officer

Daniel Pereira

        

Vice President

Vicki Sung

        

VP - Finance

Galit Yaakobovitz

        

VP - Operations

Kevin Romanko

        

VP - R & D

Arun Kashyap

        

VP - Regulatory Affairs

Michele DeVries

        

Browse more venture capital transactions:

Prev: 3/26/2019: Ouster venture capital transaction
Next: 3/26/2019: Mursion venture capital transaction

Share this article

About Our Venture Capital Transactions Database

We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary